Ocugen Inc (OCGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $262.28M
Last updated: Nov 17, 2026 at 4:42 PM ET
Ocugen Inc (OCGN) Statistics
Ocugen (OCGN) has a market cap of $262.28M and an enterprise value of $239.43M. It kept -1367.61% of revenue as net income over the last 12 months. Its share count is up 11.58% from a year earlier.
Total Valuation
Enterprise value is 8.71% below the market cap, as cash exceeds debt.
| Market Cap | $262.28M |
|---|---|
| Enterprise Value | $239.43M |
| Latest price (Nov 17, 2026) | $0.76 |
Key Dates
The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 53.7x. Its year-end P/S ranged from 6.1x to 115.0x from 2020 to 2025.
| P/S Ratio | 53.7x |
|---|---|
| Forward P/S | 45.3x |
Price Statistics
The stock is down 36.41% over 52 weeks and trades 16.48% below its 50-day average.
| Beta (1Y) | 1.76 |
|---|---|
| 52-Week Change | -36.41% |
| 1-Month Change | -3.89% |
| 3-Month Change | -48.87% |
| 6-Month Change | -41.79% |
| 5-Year Change | -94.07% |
| 10-Year Change | -99.56% |
| Total Return (1Y) | -36.41% |
| Total Return (5Y CAGR) | -36.40% |
| Max Drawdown (1Y) | -71.67% |
| Max Drawdown (3Y) | -73.92% |
| Sharpe Ratio (1Y) | -0.51 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $0.91 |
| 200-Day Average | $1.38 |
| 52-Week Range | $0.69 to $2.73 |
| RSI (14 Days) | 40.5 |
| Average Volume (20 Days) | 7.50M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.77x current liabilities.
| Current Ratio | 0.77x |
|---|---|
| Quick Ratio | 0.77x |
| Interest Coverage | -4.33x |
Returns and Efficiency
Return on invested capital is 271.00% over the last 12 months.
| Return on Assets (ROA) | -60.48% |
|---|---|
| Return on Invested Capital (ROIC) | 271.00% |
| ROA (5Y Average) | -90.86% |
| Asset Turnover | 0.06x |
Scores
OCGN has an Altman Z-Score of -6.61, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -6.61 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $4.78M over the last 12 months is down 11.01% from the 12 months before.
| Revenue | $4.78M |
|---|---|
| Revenue Growth (YoY) | -11.01% |
| Gross Profit | $4.78M |
| Operating Income | -$69.03M |
| Pretax Income | -$65.18M |
| Net Income | -$65.36M |
| EBITDA | -$50.16M |
| EBIT | -$54.55M |
| Reported EPS (TTM) | -$0.25 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $24.63M |
|---|---|
| Total Debt | $1.78M |
| Net Cash | $22.85M |
| Net Cash Per Share | $0.07 |
| Working Capital | -$27.47M |
| Shareholder Equity | -$17.68M |
| Total Assets | $108.06M |
| Total Liabilities | $125.74M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $211.00K of capital spending, operating cash flow left -$63.90M of free cash flow.
| Operating Cash Flow | -$63.69M |
|---|---|
| Capital Expenditures | $211.00K |
| Free Cash Flow | -$63.90M |
| FCF Per Share | -$0.19 |
| Depreciation and Amortization | $5.19M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1444.47%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -1444.47% |
| Pretax Margin | -1363.86% |
| Net Margin | -1367.61% |
| EBITDA Margin | -1049.53% |
| EBIT Margin | -1141.54% |
| FCF Margin | -1337.16% |
Growth
Revenue grew 21.05% a year over 3 years.
| Revenue Growth (3Y CAGR) | +21.05% |
|---|---|
| Revenue Growth (5Y CAGR) | +152.50% |
Dividends and Yields
OCGN does not pay a dividend. Its free cash flow yield is -24.90%.
| FCF Yield | -24.90% |
|---|---|
| Buyback Yield | -9.00% |
| Shareholder Yield | -9.00% |
Stock Splits
The last split was a 1-for-60 reverse split on Sep 30, 2019.
| Last Split Date | Sep 30, 2019 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:60 |
Peer Position
Against 6 similar companies, OCGN has the 2nd highest P/S.
P/S RatioPeer median 8.6x
ROICPeer median -42.31%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -78.05%
| P/S Ratio | 53.7x vs 8.6x median |
|---|---|
| ROIC | 271.00% vs -42.31% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -11.01% vs -78.05% median |
Analyst Forecast
Consensus estimates put revenue growth at 28.91% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +28.91% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About OCGN
What is OCGN's market cap?
Ocugen has a market cap of $262.28M. Its enterprise value, which adds debt and subtracts cash, is $239.43M.
How many shares of OCGN are outstanding?
Ocugen has 339.21M shares outstanding. The count is up 11.58% from a year earlier.
Does OCGN pay a dividend?
No. Ocugen does not pay a dividend.
How much debt does OCGN have?
Ocugen has $1.78M of total debt and $24.63M of cash and equivalents, a net cash position of $22.85M.
OCGN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors